Real‐world use of cenobamate in pediatric focal epilepsies and developmental epileptic encephalopathies: A multicenter retrospective series
Epilepsia · 2025-12 · 66 (12) · 4712-4724
DOI: 10.1111/epi.18586 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsia, online erschienen am 30.07.2025. Verfasst von Víctor Soto-Insuga und 29 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Infantil Niño Jesús, Madrid, Spain. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsies, Partial, Carbamates, Drug Resistant Epilepsy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Epilepsy Study Group of the Spanish Society of Pediatric Neurology (SENEP), Vithas Foundation.
Abstract (Originalsprache)
Objective
Cenobamate (CNB) is an anti‐seizure medication approved for focal‐onset seizures in adults, with growing evidence supporting its use in pediatric drug‐resistant epilepsy (DRE). This study evaluates the efficacy, retention, and safety of CNB in children and adolescents, including those with developmental and epileptic encephalopathies (DEEs).
Methods
We conducted a retrospective, multicenter study of 169 pediatric patients (0–18 years) with DRE treated with CNB across centers in Spain. Seizure response (≥50% reduction) and seizure freedom (no seizures in the previous month) were assessed at 3, 6, and 12 months.
Results
At 12 months, CNB showed a retention rate of 89.2%, with 83.9% of patients achieving seizure response and 19.6% reaching seizure freedom. Response rates were 73.4% at 3 months and 77.1% at 6 months, with seizure freedom increasing from 11.8% at 3 months to 21.1% at 6 months. Outcomes were comparable between DEEs and focal epilepsies, indicating broad‐spectrum efficacy. Seizure worsening occurred in 4.7% of patients, all with DEEs. After adjusting for seizure type, those patients with focal seizures had higher odds of achieving seizure response (odds ratio [OR] 95% confidence interval [95% CI] 5.46, 1.27–23.52; p = 0.02) and seizure freedom (OR 95% CI 5.32, 1.57–17.97; p < 0.01). Median CNB doses (mg/kg/day) were 1.78 (range 0.37–12.5), 2.5 (range 0.67–12.5), and 3.19 (range 0.96–9.09) at 3, 6, and 12 months, respectively. Adverse events occurred in 44.9% of patients, most commonly somnolence (42.3%) and dizziness (22.4%), which improved with slower titration. Significance CNB appears effective and well‐tolerated in pediatric DRE, including DEE, with high retention and sustained efficacy over time. Adverse events were generally manageable with dose adjustments, and slow, weight‐based titration improved tolerability. Prospective studies are warranted to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Infantil Niño Jesús, Madrid, Spain.
- Epilepsy Unit-Vithas Madrid University Hospitals, Madrid, Spain.
- Hospital Universitario Marqués de Valdecilla, Santander, Spain.
- Consorci Mar Parc de Salut de Barcelona, Barcelona, Spain.
- Hospital Virgen de la Arrixaca, Murcia, Spain.
- Hospital Universitario Ramón y Cajal, Madrid, Spain.
ORCID-Profile: Víctor Soto-Insuga, Adrián Valls Carbó, Elena González-Alguacil, Salvador Ibáñez-Micó, Jana DomínguezCarral, Dolors Casellas, Virginia Navarro, Antonio Gil Nagel-Rein, María Muñoz Cabeza, Ángel Aledo-Serrano
Förderung
- Epilepsy Study Group of the Spanish Society of Pediatric Neurology (SENEP)
- Vithas Foundation
Zitieren
APA
Soto-Insuga, V., Valls Carbó, A., Pinzón-Acevedo, A. G., González-Alguacil, E., Peñas, J. J. G., Jamardo, A. S., Aznar-Laín, G., Ibáñez-Micó, S., Martínez, H. A., Buenache, R., Rekarte, S., Olivera, A. P., Tuero-Montiel, E., DomínguezCarral, J., López, M., Ribes, A. G., González, M. J. M., Arias, E., Ron, A. G., …, & Aledo-Serrano, Á. (2025). Real‐world use of cenobamate in pediatric focal epilepsies and developmental epileptic encephalopathies: A multicenter retrospective series. Epilepsia, 66(12), 4712-4724. https://doi.org/10.1111/epi.18586
Vancouver
Soto-Insuga V, Valls Carbó A, Pinzón-Acevedo AG, González-Alguacil E, Peñas JJG, Jamardo AS, et al. Real‐world use of cenobamate in pediatric focal epilepsies and developmental epileptic encephalopathies: A multicenter retrospective series. Epilepsia. 2025;66(12):4712-4724. doi:10.1111/epi.18586
BibTeX
@article{SotoInsuga2025,
author = {Soto-Insuga, Víctor and Valls Carbó, Adrián and Pinzón-Acevedo, Anna Gretel and González-Alguacil, Elena and Peñas, Juan José García and Jamardo, Andrea Sariego and Aznar-Laín, Gemma and Ibáñez-Micó, Salvador and Martínez, Helena Alarcón and Buenache, Raquel and Rekarte, Saray and Olivera, Andrea Parejo and Tuero-Montiel, Ezequiel and DomínguezCarral, Jana and López, María and Ribes, Ainhoa García and González, María Jesús Martínez and Arias, Eva and Ron, Adrián García and Boronat, Susana and Viñas, Eulalia Turón and Casellas, Dolors and Navarro, Virginia and Conejo, David and Miravet, Elena and Román, Irene Sánchez-Miranda and Nagel-Rein, Antonio Gil and Cabeza, María Muñoz and Smeyers, Patricia and Aledo-Serrano, Ángel},
title = {Real‐world use of cenobamate in pediatric focal epilepsies and developmental epileptic encephalopathies: A multicenter retrospective series},
journal = {Epilepsia},
year = {2025},
volume = {66},
number = {12},
pages = {4712--4724},
doi = {10.1111/epi.18586}
}
EUVIMED